EP1082109B1 - Oral formulation comprising biguanide and an organic acid - Google Patents
Oral formulation comprising biguanide and an organic acid Download PDFInfo
- Publication number
- EP1082109B1 EP1082109B1 EP99917144A EP99917144A EP1082109B1 EP 1082109 B1 EP1082109 B1 EP 1082109B1 EP 99917144 A EP99917144 A EP 99917144A EP 99917144 A EP99917144 A EP 99917144A EP 1082109 B1 EP1082109 B1 EP 1082109B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- acid
- oral formulation
- biguanide
- solution
- formulation according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Definitions
- the present invention relates to an oral fomulation comprising a biguanide and an organic acid.
- metformin has unpleasant tastes such as bitterness and saltiness.
- the dosages of metformin are about 250 mg per dose in Japan and about 850 mg per dose in United States of America. In spite of such big dosages, only tablets are on sale at present.
- Powders, fine granules and granules are formulated with sweetening agents or flavors; microcapsules, non-enteric coated formulation, spray-dried formulation with low melting point wax, formulation with lecithin (JP 62-265234-A) and the like may also be used.
- the inventors of the present invention have intensively carried out research, and found that an oral formulation comprising a biguanide and an organic acid has less unpleasant tastes such as bitterness and saltiness. Thus, the present invention has been accomplished.
- the present inventions includes:
- Biguanide includes compounds having a biguanide structure such as metformin, buformin, phenformin and pharmaceutically acceptable salts thereof.
- Organic acid includes malic acid, citric acid, tartaric acid, ascorbic acid, succinic acid, fumaric acid, maleic acid, gluconic acid, glucuronic acid and mixtures thereof.
- Preferable organic acids are organic acids having 2 or 3 carboxyl groups such as malic acid, citric acid and tartaric acid, more preferably malic acid.
- the ratio (w/w) of the biguanide to the organic acid is, for example, 1 : 0.01 to 1 : 50, preferably 1 : 0.02 to 1 : 10, more preferably 1 : 0.05 to 1 : 1.
- the preferable ratio (w/w) of the biguanide to malic acid is 1 : 0.05 to 1 : 0.5.
- “Sweetening agent” includes aspartameTM, saccharin, saccharin sodium, stevioside, thaumatin, erythritol, sorbitol, xylitol, glycerin and mixtures thereof.
- Preferable sweetening agents are aspartameTM, saccharin, saccharin sodium and stevioside.
- the ratio (w/w) of the biguanide to the sweetening agent is, for example, 1 : 0.001 to 1 : 10, preferably 1 : 0.02 to 1 : 1.
- the pH of the solution is 3.5 to 6, more preferably 4 to 6, to decrease the unpleasant tastes and to keep the biguanide stable.
- the preferable pH of the solution or dispersion which is formed by dispersing the formulation in water (1 part of the formulation to 10 parts of water, by weight) is 3.5 to 6, more preferably 4 to 6; This is in order to decrease the unpleasant tastes and to keep the biguanide stable.
- Oral formulation includes solution, jelly, gum drops, dry syrup, powders, fine granules and granules. Preferably the formulation is not in the form of tablets.
- the formulation of the present invention may include pharmaceutically acceptable non-toxic and inactive additives.
- Additives include excipients such as corn starch, potato starch, white sugar, mannitol, xylitol, sorbitol, talc, kaolin, calcium monohydrogen phosphate, calcium sulfate, calcium carbonate, crystalline cellulose; lubricants such as magnesium stearate and potassium stearate; disintegrators such as carboxymethylcellulose calcium and low substituted hydroxymethylcellulose; binders such as hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinypyrrolidone, gelatin, methylcellulose, Arabia gum and polyvinylalcohol; coloring agents; correctives; adsorbents; preservatives; stabilizers; moistening agents; de-charging agents; pH adjusters.
- the formulation may include flavors such as lemon, orange, grapefruit, pine, banana, chocolate and yogurt to decrease the unpleasant tastes more.
- the formulation of the present invention can be prepared by well known methods.
- the formulation can be prepared, for example, by extruding granulation methods, crushing granulation methods, dry granulation methods, fluidized bed granulation methods, tumbling granulation methods, high shear mixing granulation methods, wet compression methods, and direct compression methods.
- the formulation of the present invention will contain the conventional amounts of active ingredient (biguanide) and will be used in conventional manner to administer doses in accordance with normal practice by routes and according to dosage regimes which are familiar to pharmacologists and medical practitioners.
- metformin hydrochloride 5 % Solution of metformin hydrochloride is prepared by dissolving metformin hydrochloride, malic acid, aspartameTM and lemon flavor into purified water.
- metformin hydrochloride 5 % Solution of metformin hydrochloride is prepared by dissolving metformin hydrochloride, malic acid, saccharine sodium and lemon flavor into purified water.
- metformin hydrochloride 5 % Solution of metformin hydrochloride is prepared by dissolving metformin hydrochloride, citric acid, aspartameTM and lemon flavor into purified water.
- metformin hydrochloride 5 % Solution of metformin hydrochloride is prepared by dissolving metformin hydrochloride, malic acid, saccharin sodium, erythritol and lemon flavor into purified water.
- metformin hydrochloride 5 % Solution of metformin hydrochloride is prepared by dissolving metformin hydrochloride, malic acid, aspartameTM, sorbitol and grapefruit flavor into purified water.
- metformin hydrochloride 5 % Solution of metformin hydrochloride is prepared by dissolving metformin hydrochloride, malic acid, saccharin, glycerin and lemon flavor into purified water.
- metformin hydrochloride 5 % Solution of metformin hydrochloride is prepared by dissolving metformin hydrochloride, malic acid, saccharin sodium, saccharin and lemon flavor into purified water.
- Meatin hydrochloride 500 g Malic acid 80 g Saccharin sodium 25 g Erythritol 865 g Polyvinylpyrrolidone K30 30 g Total 1500 g
- Metformin hydrochloride, mal ic acid, saccharin sodium, erythritol and polyvinylpyrrolidone K30 are mixed with 200 g of mixture of purified water and ethanol (1 : 1 (w/w)) to give wet solid.
- 33 % Dry syrup of metformin hydrochloride is prepared by milling the wet solid with a granulation mill to adjust the size of the granules, followed by drying.
- Jelly of metformin hydrochloride is prepared by dissolving or dispersing metformin hydrochloride, malic acid, aspartameTM and lemon flavor into gelatin solution which is made by dissolving gelatin to purified water over 80°C, followed by cooling.
- Buformin hydrochloride, mannitol, lactose, corn starch, malic acid, aspartameTM and methylcellulose are mixed with 200 g of purified water to give wet solid. 10 % Fine granules of buformin hydrochloride are prepared by granulating the wet solid with a basket granulation mill, followed by drying.
- Gum drops of buformin hydrochloride are prepared by dissolving or dispersing buformin hydrochloride, citric acid, saccharin sodium, sorbitol and lemon flavor into gelatin solution which is made by dissolving gelatin to purified water over 80 °C, followed by molding the mixture and cooling.
- 10 % powders of buformin hydrochloride are prepared by mixing buformin hydrochloride, mannitol, corn starch, citric acid, aspartameTM and magnesium stearate.
- Metformin hydrochloride is not stable below pH 3.5, and the solution tastes sour. The solution over pH 7 has bitterness.
- the present invention provides an oral formulation of biguanide with less unpleasant tastes, With this invention, people in every age group, for example, elderly people and little children can easily have sufficient amount of biguanide.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP13612698 | 1998-04-29 | ||
JP13612698 | 1998-04-29 | ||
PCT/JP1999/002192 WO1999055320A1 (en) | 1998-04-29 | 1999-04-26 | Oral formulation comprising biguanide and an organic acid |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1082109A1 EP1082109A1 (en) | 2001-03-14 |
EP1082109B1 true EP1082109B1 (en) | 2004-06-16 |
Family
ID=15167924
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99917144A Expired - Lifetime EP1082109B1 (en) | 1998-04-29 | 1999-04-26 | Oral formulation comprising biguanide and an organic acid |
Country Status (11)
Country | Link |
---|---|
US (1) | US6517870B1 (es) |
EP (1) | EP1082109B1 (es) |
JP (1) | JP5255604B2 (es) |
AT (1) | ATE269069T1 (es) |
AU (1) | AU3536299A (es) |
CA (1) | CA2330485C (es) |
DE (1) | DE69918105T2 (es) |
DK (1) | DK1082109T3 (es) |
ES (1) | ES2224634T3 (es) |
PT (1) | PT1082109E (es) |
WO (1) | WO1999055320A1 (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0302700A3 (en) | 2000-08-07 | 2005-05-30 | Ranbaxy Signature Llc Princeto | Liquid formulation of metformin and its use |
JP4706096B2 (ja) * | 2000-10-23 | 2011-06-22 | 大正製薬株式会社 | 不快な味を呈する塩基性薬物配合製剤 |
FR2818908B1 (fr) * | 2000-12-29 | 2004-04-02 | Dospharma | Utilisation en tant que medicament d'un compose restituant in vivo des principes actifs |
FR2818906B1 (fr) * | 2000-12-29 | 2004-04-02 | Dospharma | Association medicamenteuse d'une biguanine et d'un transporteur, par exemple de metformine et d'arginine |
US20030021761A1 (en) | 2001-01-18 | 2003-01-30 | Geltex Pharmaceuticals, Inc. | Ionene polymers and their use in treating mucositis |
US7220312B2 (en) * | 2002-03-13 | 2007-05-22 | Micron Technology, Inc. | Methods for treating semiconductor substrates |
US7959946B2 (en) | 2002-09-20 | 2011-06-14 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US7785627B2 (en) | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US8084058B2 (en) | 2002-09-20 | 2011-12-27 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US9060941B2 (en) | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US8992980B2 (en) | 2002-10-25 | 2015-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Water-soluble meloxicam granules |
US20070053939A1 (en) * | 2003-10-17 | 2007-03-08 | Hideakira Yokoyama | Biguanide drug-containing jelly preparation |
KR20060126688A (ko) * | 2003-12-09 | 2006-12-08 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 약물-함유 입자 및 그 입자를 함유하는 고형 제제 |
DE10360924A1 (de) * | 2003-12-23 | 2005-07-28 | IIP - Institut für industrielle Pharmazie, Forschungs- und Entwicklungsgesellschaft mbH | Metformin-haltige pharmazeutische Zusammensetzung |
EP1568369A1 (en) | 2004-02-23 | 2005-08-31 | Boehringer Ingelheim Vetmedica Gmbh | Use of meloxicam for the treatment of respiratory diseases in pigs |
DE102005006539A1 (de) * | 2005-02-11 | 2006-08-24 | Merck Patent Gmbh | Biguanid enthaltende Zusammensetzungen |
UY29445A1 (es) * | 2005-03-30 | 2006-10-02 | Generex Pharm Inc | Composiciones para la transmisión transmucosa oral de la metformina |
PT1878426E (pt) * | 2005-04-26 | 2010-06-28 | Dainippon Sumitomo Pharma Co | Preparação granulada contendo um composto de biguanida |
CA2620219A1 (en) * | 2005-11-02 | 2007-05-18 | Teikoku Pharma Usa, Inc. | Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same |
US20080107787A1 (en) * | 2006-11-02 | 2008-05-08 | The Coca-Cola Company | Anti-Diabetic Composition with High-Potency Sweetener |
WO2008097861A2 (en) * | 2007-02-02 | 2008-08-14 | Braincells, Inc. | MODULATION OF NEUROGENESIS WITH BIGUANIDES AND GSK3-ß AGENTS |
EP2170063A1 (en) * | 2007-07-23 | 2010-04-07 | Teikoku Pharma USA, Inc. | Organoleptically acceptable indole serotonin receptor agonist oral dosage formulations and methods of using the same |
US9795568B2 (en) | 2010-05-05 | 2017-10-24 | Boehringer Ingelheim Vetmedica Gmbh | Low concentration meloxicam tablets |
WO2011154975A2 (en) | 2010-06-08 | 2011-12-15 | Cadila Healthcare Limited | Pharmaceutical compositions of metformin |
WO2013055609A1 (en) | 2011-10-12 | 2013-04-18 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions that inhibit disproportionation |
US9382187B2 (en) | 2012-07-10 | 2016-07-05 | Thetis Pharmaceuticals Llc | Tri-salt form of metformin |
US8765811B2 (en) | 2012-07-10 | 2014-07-01 | Thetis Pharmaceuticals Llc | Tri-salt form of metformin |
US9505709B2 (en) | 2014-05-05 | 2016-11-29 | Thetis Pharmaceuticals Llc | Compositions and methods relating to ionic salts of peptides |
US9242008B2 (en) | 2014-06-18 | 2016-01-26 | Thetis Pharmaceuticals Llc | Mineral amino-acid complexes of fatty acids |
ES2706493T3 (es) | 2014-06-18 | 2019-03-29 | Thetis Pharmaceuticals Llc | Complejos de aminoácidos minerales de agentes activos |
EP3795179A1 (en) | 2016-06-03 | 2021-03-24 | Thetis Pharmaceuticals LLC | Compositions and methods relating to salts of specialized pro-resolving mediators of inflammation |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB539076A (en) | 1940-03-18 | 1941-08-27 | Mergenthaler Setzmaschfab Gmbh | Improvements in or relating to typographical composing machines |
DE2124256A1 (en) * | 1971-05-15 | 1972-11-30 | Dr Christian Brunnengraber Chemi sehe Fabrik & Co mbH 2400 Lübeck | Oral antidiabetics - contg dicarboxylic amino acids |
JPS5840529B2 (ja) * | 1975-09-29 | 1983-09-06 | 明治製菓株式会社 | ケイコウヨウセイザイノセイホウ |
US4089957A (en) | 1976-06-11 | 1978-05-16 | Ab Kabi | Therapeutic compositions against recurrent thrombosis |
US5324748A (en) | 1981-07-14 | 1994-06-28 | Efamol Limited | Method for enhancement of 1-series PG production |
JPS60246325A (ja) * | 1984-05-18 | 1985-12-06 | Takeda Chem Ind Ltd | 苦味が軽減された苦味成分含有水性溶液 |
FR2611500B1 (fr) * | 1987-03-06 | 1990-05-04 | Lipha | Emploi de derives du biguanide dans la preparation de medicaments |
JP2643260B2 (ja) | 1988-03-22 | 1997-08-20 | 藤沢薬品工業株式会社 | シロップ剤 |
US4975465A (en) * | 1989-03-28 | 1990-12-04 | American Home Products Corporation | Orally administrable ibuprofen compositions |
US5260275A (en) | 1990-08-14 | 1993-11-09 | Amylin Pharmaceuticals, Inc. | Hypoglycemics |
US5411755A (en) * | 1993-02-16 | 1995-05-02 | The Procter & Gamble Company | Process and composition for sweet juice from cucurbitaceae fruit |
JP2705787B2 (ja) | 1994-09-30 | 1998-01-28 | 山之内製薬株式会社 | 苦味改善易服用性h▲2▼ブロッカー固形製剤 |
JP3294033B2 (ja) * | 1994-12-24 | 2002-06-17 | 俊博 森田 | オブラート |
JPH104939A (ja) * | 1996-06-27 | 1998-01-13 | Nippon Shinyaku Co Ltd | 飲 料 |
JPH1036252A (ja) | 1996-07-22 | 1998-02-10 | Taisho Pharmaceut Co Ltd | ベラドンナ(総)アルカロイド配合内服液剤 |
JP3658878B2 (ja) * | 1996-08-05 | 2005-06-08 | 大正製薬株式会社 | 内服液剤 |
EP1004304A4 (en) * | 1996-12-24 | 2002-10-16 | Sumitomo Pharma | COMPOSITION WITH ACORBIC ACID |
ATE261935T1 (de) * | 1997-12-08 | 2004-04-15 | Bristol Myers Squibb Co | Neue metformin salze und verfahren |
-
1999
- 1999-04-26 PT PT99917144T patent/PT1082109E/pt unknown
- 1999-04-26 ES ES99917144T patent/ES2224634T3/es not_active Expired - Lifetime
- 1999-04-26 US US09/674,150 patent/US6517870B1/en not_active Expired - Lifetime
- 1999-04-26 AU AU35362/99A patent/AU3536299A/en not_active Abandoned
- 1999-04-26 EP EP99917144A patent/EP1082109B1/en not_active Expired - Lifetime
- 1999-04-26 AT AT99917144T patent/ATE269069T1/de active
- 1999-04-26 DK DK99917144T patent/DK1082109T3/da active
- 1999-04-26 WO PCT/JP1999/002192 patent/WO1999055320A1/en active IP Right Grant
- 1999-04-26 CA CA002330485A patent/CA2330485C/en not_active Expired - Fee Related
- 1999-04-26 DE DE69918105T patent/DE69918105T2/de not_active Expired - Lifetime
-
2010
- 2010-06-18 JP JP2010139891A patent/JP5255604B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP5255604B2 (ja) | 2013-08-07 |
DE69918105T2 (de) | 2005-07-07 |
JP2010195839A (ja) | 2010-09-09 |
ES2224634T3 (es) | 2005-03-01 |
CA2330485C (en) | 2008-07-08 |
ATE269069T1 (de) | 2004-07-15 |
DK1082109T3 (da) | 2004-08-09 |
EP1082109A1 (en) | 2001-03-14 |
DE69918105D1 (de) | 2004-07-22 |
CA2330485A1 (en) | 1999-11-04 |
WO1999055320A1 (en) | 1999-11-04 |
US6517870B1 (en) | 2003-02-11 |
AU3536299A (en) | 1999-11-16 |
PT1082109E (pt) | 2004-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1082109B1 (en) | Oral formulation comprising biguanide and an organic acid | |
US6106861A (en) | Multiparticulate tablet disintegrating in less than 40 seconds in the mouth | |
RU2184570C2 (ru) | Препараты для орального введения | |
US6242002B1 (en) | Effervescent formulations | |
EP1370247B1 (en) | Taste masked pharmaceutical compositions | |
US6475510B1 (en) | Process for manufacturing bite-dispersion tablets | |
US6187336B1 (en) | Process for producing a solid which is rapidly soluble in the oral cavity | |
US6245353B1 (en) | Solid, rapidly disintegrating cetirizine formulations | |
CA2540040C (en) | Rapidly disintegrating formulation | |
NZ229698A (en) | Effervescent composition comprised of ranitidine, a mono alkali metal citrate and an alkaline carbonate or bicarbonate | |
SK48395A3 (en) | Ranitidine chewable tablets | |
KR20100008007A (ko) | 구강내에서 신속하게 붕괴되는 정제 | |
HU207948B (en) | Process for producing oral pimobendane compositions | |
US5468504A (en) | Effervescent pharmaceutical compositions | |
JP4501024B2 (ja) | システイン類の苦味及び臭気が軽減された組成物 | |
JP4606582B2 (ja) | ビグアナイド系薬物の内服製剤 | |
JPH05306229A (ja) | カルシウム含有チユアブル錠 | |
ZA200108820B (en) | Prucalopride oral solution. | |
WO2005072717A1 (ja) | ビグアナイド系薬物の内服製剤 | |
JP3110299B2 (ja) | 成形物およびその製造方法 | |
EP1188441A1 (en) | Oral preparations of etidronate disodium | |
JP2010053048A (ja) | 苦味が緩和されたイルベサルタン含有医薬組成物 | |
US20230414597A1 (en) | Orodispersible powder composition comprising an antihistamine compound | |
CA2099585C (en) | Pharmaceutical compositions | |
WO2024005767A1 (en) | A taste masked solid composition of zinc active |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20001011 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20021218 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REF | Corresponds to: |
Ref document number: 69918105 Country of ref document: DE Date of ref document: 20040722 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: BOVARD AG PATENTANWAELTE |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20040402532 Country of ref document: GR |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20040827 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2224634 Country of ref document: ES Kind code of ref document: T3 |
|
ET | Fr: translation filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050426 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20050426 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050430 |
|
26N | No opposition filed |
Effective date: 20050317 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PUE Owner name: DAINIPPON PHARMACEUTICAL CO., LTD. Free format text: SUMITOMO PHARMACEUTICALS COMPANY, LIMITED#2-8, DOSHOMACHI 2-CHOME, CHUO-KU#OSAKA-SHI, OSAKA 541-8510 (JP) -TRANSFER TO- DAINIPPON PHARMACEUTICAL CO., LTD.#6-8, DOSHO-MACHI 2-CHOME CHUO-KU#OSAKA-SHI (JP) Ref country code: CH Ref legal event code: PFA Owner name: DAINIPPON SUMITOMO PHARMA CO., LTD. Free format text: DAINIPPON PHARMACEUTICAL CO., LTD.#6-8, DOSHO-MACHI 2-CHOME CHUO-KU#OSAKA-SHI (JP) -TRANSFER TO- DAINIPPON SUMITOMO PHARMA CO., LTD.#6-8, DOSHO-MACHI 2-CHOME CHUO-KU OSAKA-SHI#OSAKA-FU (JP) |
|
NLS | Nl: assignments of ep-patents |
Owner name: DAINIPPON PHARMACEUTICAL CO. LTD. Effective date: 20060131 |
|
NLT1 | Nl: modifications of names registered in virtue of documents presented to the patent office pursuant to art. 16 a, paragraph 1 |
Owner name: DAINIPPON SUMITOMO PHARMA CO. LTD. |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: PC2A |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: PC4A Owner name: DAINIPPON SUMITOMO PHARMA CO.LTD, JP Effective date: 20060320 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: TP |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: BOVARD AG PATENTANWAELTE |
|
BECN | Be: change of holder's name |
Owner name: *DAINIPPON SUMITOMO PHARMA CO. LTD Effective date: 20060314 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: DAINIPPON SUMITOMO PHARMA CO., LTD. Free format text: DAINIPPON SUMITOMO PHARMA CO., LTD.#6-8, DOSHO-MACHI 2-CHOME CHUO-KU OSAKA-SHI#OSAKA-FU (JP) -TRANSFER TO- DAINIPPON SUMITOMO PHARMA CO., LTD.#6-8, DOSHO-MACHI 2-CHOME CHUO-KU OSAKA-SHI#OSAKA-FU (JP) |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20160411 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20160411 Year of fee payment: 18 Ref country code: IE Payment date: 20160411 Year of fee payment: 18 Ref country code: GR Payment date: 20160415 Year of fee payment: 18 Ref country code: ES Payment date: 20160412 Year of fee payment: 18 Ref country code: FI Payment date: 20160411 Year of fee payment: 18 Ref country code: GB Payment date: 20160420 Year of fee payment: 18 Ref country code: DE Payment date: 20160419 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20160411 Year of fee payment: 18 Ref country code: IT Payment date: 20160428 Year of fee payment: 18 Ref country code: SE Payment date: 20160412 Year of fee payment: 18 Ref country code: PT Payment date: 20160422 Year of fee payment: 18 Ref country code: FR Payment date: 20160412 Year of fee payment: 18 Ref country code: DK Payment date: 20160412 Year of fee payment: 18 Ref country code: BE Payment date: 20160413 Year of fee payment: 18 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 69918105 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP Effective date: 20170430 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20170501 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 269069 Country of ref document: AT Kind code of ref document: T Effective date: 20170426 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20170426 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20171229 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170501 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170502 Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170426 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171103 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170426 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170427 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170426 Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171026 Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171103 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170430 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170430 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20170430 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170426 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170430 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170426 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170430 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20180629 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170427 |